Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD)—the β‐amyloid peptide (Aβ) and tau—are promising therapeutic avenues against AD. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.